IL25 and asthma: Although blockade to the IL-25 pathway is a validated therapeutic approach to asthma in pre-clinical studies, clinical application of targeting the IL-25 pathway is still lacking except a Phase I clinical trial of an IL-25 neutralizing antibody launched in 2023 (NCT05128409) (24).